Menu General Meeting Overview General Meeting archive Proposed transaction with Pfizer, Inc to form a new Consumer Healthcare Joint Venture At a General Meeting held on Wednesday 8 May 2019 at the Sofitel London Heathrow Terminal 5, London Heathrow Airport, TW6 2GD shareholders approved the proposed transaction with Pfizer, Inc to form a new Consumer Healthcare Joint Venture. The voting results can be found here. The Circular to Shareholders and Notice of General Meeting (PDF - 392.6KB) gives details on the resolution put to the meeting, together with explanatory notes. Previously published documents relating to the proposed transaction: Read the GSK press release dated 19 December 2018 Analyst call dated 19 December 2018: View the slides (PDF) View the transcript (PDF) In accordance with section 311A of the Companies Act 2006, GSK confirms that, as at 1 April 2019, its issued share capital (excluding Treasury shares) consisted of 4,987,659,065 ordinary shares of 25 pence each, carrying one vote each. Therefore, the total voting rights that members are entitled to exercise at the AGM in respect of these shares is 4,987,659,065. Information about our previous General Meetings is available from the General Meeting archive tab above. Find out more Investors Information and tools for investors including share and dividend information, share price analysis, latest news and corporate reporting Quarterly results Discover our latest financial performance announcement and search for historical quarterly results materials Speeches & presentations Search through our archive of speeches and presentations from conferences and events Back to top RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL